(8-Hydroxy-1-methyl-12,17-dioxo-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2,4,6,8,10,13(20),15-heptaen-5-yl) hydrogen sulfate

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: (8-Hydroxy-1-methyl-12,17-dioxo-14-oxapentacyclo[11.6.1.02,11.04,9.016,20]icosa-2,4,6,8,10,13(20),15-heptaen-5-yl) hydrogen sulfate
• 化学式: C₂₀H₁₄O₈S
• 分子量: 414.4
• InChiKey: OIBVHMHPAKLZEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  140
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• JPH03173881A
  申请人：——

  公开号：JPH03173881A

  公开（公告）日：1991-07-29
• JPH07196595A
  申请人：——

  公开号：JPH07196595A

  公开（公告）日：1995-08-01
• Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
  申请人：ANDERSEN Raymond J.

  公开号：US20090042868A1

  公开（公告）日：2009-02-12

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.
• US7799776B2
  申请人：——

  公开号：US7799776B2

  公开（公告）日：2010-09-21